EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 20 of the 23 references it cites were found in a registry or an index.
Abstract
Background/Purpose: Treating neovascular age-related macular degeneration with intravitreal aflibercept treat-and-extend (T&E) can reduce treatment burden. ARIES assessed whether intravitreal aflibercept early-start T&E was noninferior to late-start T&E. Methods: A randomized, open-label, Phase 3b/4 study that included treatment-naïve patients aged ≥50 years with the best-corrected visual acuity 73–25 Early Treatment Diabetic Retinopathy Study letters and active choroidal neovascularization secondary to AMD. Patients received 2 mg intravitreal aflibercept at Week (W) 0, W4, W8, and W16. At W16, patients were randomized 1:1 to early-start (2W interval adjustments) or late-start T&E (8W intervals until W48 then 2W interval adjustments). Primary endpoint: the best-corrected visual acuity change from randomization to W104. Results: Two-hundred seventy-one patients were randomized. The mean (SD) best-corrected visual acuity at baseline was 60.2 (12.1; early-T&E) and 61.3 (10.8; late-T&E) letters. The mean (SD) best-corrected visual acuity change (W16–104) was −2.1 (11.4) versus −0.4 (8.4) letters (early-T&E vs. late-T&E; least-squares mean difference: −2.0; 95% confidence interval: −4.75 to 0.71; P = 0.0162 for noninferior); +4.3 (13.4) versus +7.9 (11.9) letters (W0–104). The mean (SD) number of injections was 12.0 (2.3) versus 13.0 (1.8). From baseline to W104, 93.4% and 96.2% maintained best-corrected visual acuity; the mean (SD) central retinal thickness change was −161.6 (135.6) µ m and −158.6 (125.1) µ m. The last injection interval (W104) was ≥12W for 47.2% and 51.9% of patients. Conclusion: Outcomes were similar between patients with neovascular age-related macular degeneration treated with an intravitreal aflibercept early-T&E or late-T&E regimen after initial dosing, with one injection difference over 2 years. Trial Registration: ClinicalTrials.gov Identifier: NCT02581891 https://clinicaltrials.gov/ct2/show/NCT02581891. Supplemental Digital Contents (files 1 http://links.lww.com/IAE/B419).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, variability in the response to anti-VEGF treatment has been observed and a small proportion of patients experience substantial vision loss (≥15 Early Treatment of Diabetic Retinopathy Study [ETDRS] letters) despite treatment.4”
From ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2 (2024) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Mechanisms of Age-Related Macular Degeneration
Ambati, J., & Fowler, B. J. (2012) · Neuron · doi:10.1016/j.neuron.2012.06.018 · Cited by 1,021
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
Schmidt-Erfurth, U., Kaiser, P. K., Korobelnik, J.-F., Brown, D. M., Chong, V., Nguyen, Q. D., Ho, A. C., Ogura, Y., Simader, C., Jaffe, G. J., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.011 · Cited by 822
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Wordsworth, S., & Reeves, B. C. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.04.015 · Cited by 781
Maguire, M. G., Martin, D. F., Ying, G.-S., Jaffe, G. J., Daniel, E., Grunwald, J. E., Toth, C. A., Ferris, F. L., & Fine, S. L. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.045 · Cited by 708
Schmidt-Erfurth, U., Chong, V., Loewenstein, A., Larsen, M., Souied, E., Schlingemann, R., Eldem, B., Monés, J., Richard, G., & Bandello, F. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305702 · Cited by 639
Self-citationFreund, K. B., Korobelnik, J.-F., Devenyi, R., Framme, C., Galic, J., Herbert, E., Hoerauf, H., Lanzetta, P., Michels, S., Mitchell, P., et al. (2015) · Retina · doi:10.1097/iae.0000000000000627 · Cited by 283
Self-citationOhji, M., Takahashi, K., Okada, A. A., Kobayashi, M., Matsuda, Y., Terano, Y., for the ALTAIR Investigators, Ohji, M., Hanemoto, T., Kaga, T., et al. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01236-x · Cited by 256
Kim, L. N., Mehta, H., Barthelmes, D., Nguyen, V., & Gillies, M. C. (2016) · Retina · doi:10.1097/iae.0000000000001142 · Cited by 184
The Vision Academy Steering Committee, Lanzetta, P., & Loewenstein, A. (2017) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-017-3647-4 · Cited by 180
Research works printed but not linked: 1
- Do, 2017, Pharmacokinetics of free aflibercept in patients with neovascular age related macular degeneration, Invest Ophthalmol Vis Sci, 58, 406
Cited by
Lanzetta, P., Korobelnik, J.-F., Heier, J. S., Leal, S., Holz, F. G., Clark, W. L., Eichenbaum, D., Iida, T., Xiaodong, S., Berliner, A. J., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00063-1 · Cited by 266
Self-citationKhanani, A. M., Kotecha, A., Chang, A., Chen, S.-J., Chen, Y., Guymer, R., Heier, J. S., Holz, F. G., Iida, T., Ives, J. A., et al. (2024) · Ophthalmology · doi:10.1016/j.ophtha.2024.02.014 · Cited by 227
Self-citationEmerging therapeutic strategies for unmet need in neovascular age-related macular degeneration
Khachigian, L. M., Liew, G., Teo, K. Y. C., Wong, T. Y., & Mitchell, P. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03937-7 · Cited by 104
Self-citationRosenberg, D., Deonarain, D. M., Gould, J., Sothivannan, A., Phillips, M., Sarohia, G. S., Sivaprasad, S., Wykoff, C. C., Cheung, C. M. G., Sarraf, D., et al. (2022) · Eye · doi:10.1038/s41433-022-02020-7 · Cited by 97
Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic
Stanga, P. E., Valentín-Bravo, F. J., Stanga, S. E. F., Reinstein, U. I., Pastor‐Idoate, S., & Downes, S. M. (2023) · Eye · doi:10.1038/s41433-023-02505-z · Cited by 91
Metadata
- Authors
- Mitchell, P., Holz, F. G., Hykin, P., Midena, E., Souied, E., Allmeier, H., Lambrou, G., Schmelter, T., Wolf, S., & on behalf of the ARIES study investigators
- Affiliations
- The University of Sydney (AU)
- University of Bonn (DE)
- Moorfields Eye Hospital (GB)
- University of Padua (IT)
- Hôpital Intercommunal de Créteil (FR)
- Bayer (Switzerland) (CH)
- Bayer (Germany) (DE)
- Department for Ophthalmology, Inselspital, University Hospital, University of Bern, Bern, Switzerland.
- Corresponding author
- Mitchell, Paul
- Allmeier, Helmut
- Lambrou, George
- Venue
- Retina
- Published
- 2021-09
- Volume
- 41
- Issue
- 9
- Pages
- 1911-1920
- ISSN
- 0275-004X (ISSN-L)
- PMC
- PMC8384251
- OpenAlex
- W3146812839
- Cited by
- 101
- References
- 23
- Citations by year
- 2026: 13 · 2025: 24 · 2024: 21 · 2023: 18 · 2022: 20 · 2021: 5
- FWCI
- 14.36
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-09-01)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Retina (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, cc-by-nc-nd)
- Funders
- Bayer HealthCare
- Allergan
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- neovascular age-related macular degeneration, aflibercept, intravitreal injection, treat-and-extend regimen, choroidal neovascularization, visual acuity, non-inferiority, treatment burden, anti-VEGF therapy, central retinal thickness, treatment-naive patients, treatment efficacy and safety, endophthalmitis
- MeSH terms
- Ranibizumab, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Macula Lutea, Male, Middle Aged, Recombinant Fusion Proteins, Time Factors, Visual Acuity, Treatment Outcome, Angiogenesis Inhibitors, Receptors, Vascular Endothelial Growth Factor, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A, Wet Macular Degeneration, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1097/iae.0000000000003128
- The paper
- Mitchell, P., Holz, F. G., Hykin, P., Midena, E., Souied, E., Allmeier, H., Lambrou, G., Schmelter, T., Wolf, S., & on behalf of the ARIES study investigators. (2021). EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial. Retina. https://doi.org/10.1097/iae.0000000000003128
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.